Search
Clarithromycin
go.drugbank.com/drugs/DB01211ApprovedInvestigationalClarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with am...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsProducts: CLARITHROMYCIN 1A PH 250MG, CLARITHROMYCIN 1A PH 500MGMoxifloxacin
go.drugbank.com/drugs/DB00218ApprovedInvestigationalMoxifloxacin is a synthetic fluoroquinolone antibiotic agent. Bayer AG developed the drug (initially called BAY 12-8039) and it is marketed worldwide (as the hydrochloride) under the brand name Avelox (in some countries also Avalox) for ...
Mixtures: Dex-Moxi PF, DexMoxiKetor PFCategories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsPyridoxine
go.drugbank.com/drugs/DB00165ApprovedInvestigationalNutraceuticalVet approvedPyridoxine is the 4-methanol form of vitamin B6, an important water-soluble vitamin that is naturally present in many foods. As its classification as a vitamin implies, Vitamin B6 (and pyridoxine) are essential nutrients required for nor...
Mixtures: PR Natal 430, Virt-PnCosibelimab
go.drugbank.com/drugs/DB15770ApprovedInvestigationalCosibelimab is a human IgG1 lambda monoclonal antibody directed against programmed death ligand-1 (PD-L1). … On December 13, 2024, cosibelimab was approved by the FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma [L52690] as the first approved anti-PD-L1 therapy in the
Synonyms: anti-Pd-l1 monoclonal antibody CK-301, IMMUNOGLOBULIN G1-LAMBDA, ANTI-(HOMO SAPIENS PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1, CD274 ANTIGEN))HUMAN MONOCLONAL ANTIBODY.GAMMA.1 HEAVY CHAIN (1-450) (HOMO SAPIENS VH (IGHV1-69*01 (94%) (IGHD)-IGHJ1Monopotassium phosphate
go.drugbank.com/drugs/DB09413ApprovedInvestigationalVet approvedIt can be used in fertilizer mixtures to reduce escape of ammonia by keeping pH low.
Mixtures: Isolyte S pH 7.4, ISOLYTE-S PH 7.4 PVC 500 ML(SETLI)Serplulimab
go.drugbank.com/drugs/DB17451ApprovedInvestigationalSerplulimab is a humanized monoclonal IgG4 antibody that acts as an immune checkpoint inhibitor by targeting the programmed cell death-1 (PD-1) receptor.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsPenpulimab
go.drugbank.com/drugs/DB16747ApprovedInvestigationalPenpulimab is a humanized monoclonal IgG1 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). … The use of an IgG1 backbone - as opposed to an IgG4 backbone as is typical in other anti-PD-1 antibodies like [nivolumab] - is intended to reduce the risk of immune-related adverse events.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsMometasone furoate
go.drugbank.com/drugs/DB14512ApprovedInvestigationalVet approvedMometasone furoate is a corticosteroid drug that can be used for the treatment of asthma, rhinitis, and certain skin conditions[FDA Label] . It has a glucocorticoid receptor binding affinity 22 times stronger than dexamethasone and highe...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersProducts: MOMETASONFUROAT 1A PH 50UGDostarlimab
go.drugbank.com/drugs/DB15627ApprovedInvestigational[L33320] PD-1 receptors are found on T-cells and, when activated, serve to inhibit immune responses - some cancers leverage this system by overexpressing PD-1 ligands, thereby effectively inhibiting the … Dostarlimab is an IgG<sub>4</sub> humanized monoclonal antibody targeted against the human programmed death receptor-1 (PD-1).
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitorsSugemalimab
go.drugbank.com/drugs/DB16641ApprovedInvestigationalSugemalimab is a fully human, full-length anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (of the IgG4 isotype) discovered by CStone Pharmaceuticals. … [L53333] The drug achieves this through a dual mechanism of action involving binding to the programmed cell death-ligand 1 (PD-L1) and also through inducing antibody-dependent cellular phagocytosis.
Categories: PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitors